RxDoctor Payments Data

Desiree Rupe

Family · New Port Richey, FLNPI 1023867918

Payments from drug & device makers

$1,988in general payments, 2019–2025

Across 67 payments — averaging $29.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$401
  • Sumitomo Pharma America, Inc.$317
  • Endo USA, Inc.$255
  • Bayer$204
  • Teleflex LLC$158
  • Novartis$103
  • plus $550 from 15 others

What the payments were for

  • Food & beverage$1,88895%
  • Education$1005%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,988 in reported general payments places this provider in the 80th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$28,889
Medicare patients
151
Services billed
717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron16$13,734
Estradiol17$1,220
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst46$963
Ciprofloxacin Hcl57$364
Tamsulosin Hcl29$351
Finasteride13$128
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav23$126
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim13$29

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$20$13,73416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 14,618 family providers in Florida.

Other family in New Port Richey

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →